WO2014096859A1 - Microparticle compositions - Google Patents
Microparticle compositions Download PDFInfo
- Publication number
- WO2014096859A1 WO2014096859A1 PCT/GB2013/053398 GB2013053398W WO2014096859A1 WO 2014096859 A1 WO2014096859 A1 WO 2014096859A1 GB 2013053398 W GB2013053398 W GB 2013053398W WO 2014096859 A1 WO2014096859 A1 WO 2014096859A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- microparticle
- microparticle composition
- lipid
- molecular
- Prior art date
Links
- 239000011859 microparticle Substances 0.000 title claims abstract description 361
- 239000000203 mixture Substances 0.000 title claims abstract description 175
- 238000003384 imaging method Methods 0.000 claims abstract description 101
- -1 phosphatidylcholine lipid Chemical class 0.000 claims abstract description 89
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims abstract description 43
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims abstract description 33
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 29
- 239000000194 fatty acid Substances 0.000 claims abstract description 29
- 229930195729 fatty acid Natural products 0.000 claims abstract description 29
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 24
- 230000009149 molecular binding Effects 0.000 claims description 107
- 230000021615 conjugation Effects 0.000 claims description 58
- 238000000034 method Methods 0.000 claims description 52
- 238000006243 chemical reaction Methods 0.000 claims description 51
- 239000007789 gas Substances 0.000 claims description 40
- 229920001223 polyethylene glycol Polymers 0.000 claims description 37
- 239000002202 Polyethylene glycol Substances 0.000 claims description 36
- 238000002372 labelling Methods 0.000 claims description 28
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 claims description 26
- 229920006395 saturated elastomer Polymers 0.000 claims description 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 22
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 229960004065 perflutren Drugs 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 239000007850 fluorescent dye Substances 0.000 claims description 14
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 229910018503 SF6 Inorganic materials 0.000 claims description 10
- 229950010592 dodecafluoropentane Drugs 0.000 claims description 10
- 125000003827 glycol group Chemical group 0.000 claims description 10
- 229960004624 perflexane Drugs 0.000 claims description 10
- KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 claims description 10
- 229950003332 perflubutane Drugs 0.000 claims description 10
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 claims description 10
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 claims description 10
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 claims description 10
- 229960000909 sulfur hexafluoride Drugs 0.000 claims description 10
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 9
- 238000012285 ultrasound imaging Methods 0.000 claims description 9
- RFCAUADVODFSLZ-UHFFFAOYSA-N 1-Chloro-1,1,2,2,2-pentafluoroethane Chemical compound FC(F)(F)C(F)(F)Cl RFCAUADVODFSLZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000004340 Chloropentafluoroethane Substances 0.000 claims description 8
- 239000004338 Dichlorodifluoromethane Substances 0.000 claims description 8
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 8
- 239000003570 air Substances 0.000 claims description 8
- MEXUFEQDCXZEON-UHFFFAOYSA-N bromochlorodifluoromethane Chemical compound FC(F)(Cl)Br MEXUFEQDCXZEON-UHFFFAOYSA-N 0.000 claims description 8
- RJCQBQGAPKAMLL-UHFFFAOYSA-N bromotrifluoromethane Chemical compound FC(F)(F)Br RJCQBQGAPKAMLL-UHFFFAOYSA-N 0.000 claims description 8
- 235000019406 chloropentafluoroethane Nutrition 0.000 claims description 8
- AFYPFACVUDMOHA-UHFFFAOYSA-N chlorotrifluoromethane Chemical compound FC(F)(F)Cl AFYPFACVUDMOHA-UHFFFAOYSA-N 0.000 claims description 8
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 8
- 229940042935 dichlorodifluoromethane Drugs 0.000 claims description 8
- 235000019404 dichlorodifluoromethane Nutrition 0.000 claims description 8
- WMIYKQLTONQJES-UHFFFAOYSA-N hexafluoroethane Chemical compound FC(F)(F)C(F)(F)F WMIYKQLTONQJES-UHFFFAOYSA-N 0.000 claims description 8
- HCDGVLDPFQMKDK-UHFFFAOYSA-N hexafluoropropylene Chemical group FC(F)=C(F)C(F)(F)F HCDGVLDPFQMKDK-UHFFFAOYSA-N 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 7
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 claims description 6
- AZSZCFSOHXEJQE-UHFFFAOYSA-N dibromodifluoromethane Chemical compound FC(F)(Br)Br AZSZCFSOHXEJQE-UHFFFAOYSA-N 0.000 claims description 6
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 6
- WSJULBMCKQTTIG-OWOJBTEDSA-N (e)-1,1,1,2,3,4,4,4-octafluorobut-2-ene Chemical compound FC(F)(F)C(/F)=C(\F)C(F)(F)F WSJULBMCKQTTIG-OWOJBTEDSA-N 0.000 claims description 4
- PWMJXZJISGDARB-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5-decafluorocyclopentane Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F PWMJXZJISGDARB-UHFFFAOYSA-N 0.000 claims description 4
- LGPPATCNSOSOQH-UHFFFAOYSA-N 1,1,2,3,4,4-hexafluorobuta-1,3-diene Chemical compound FC(F)=C(F)C(F)=C(F)F LGPPATCNSOSOQH-UHFFFAOYSA-N 0.000 claims description 4
- 239000004341 Octafluorocyclobutane Substances 0.000 claims description 4
- 239000001569 carbon dioxide Substances 0.000 claims description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229910052743 krypton Inorganic materials 0.000 claims description 4
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 claims description 4
- BCCOBQSFUDVTJQ-UHFFFAOYSA-N octafluorocyclobutane Chemical compound FC1(F)C(F)(F)C(F)(F)C1(F)F BCCOBQSFUDVTJQ-UHFFFAOYSA-N 0.000 claims description 4
- 235000019407 octafluorocyclobutane Nutrition 0.000 claims description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 4
- 229910052724 xenon Inorganic materials 0.000 claims description 4
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002872 contrast media Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- JVXZRNYCRFIEGV-UHFFFAOYSA-M dilC18(3) dye Chemical group [O-]Cl(=O)(=O)=O.CC1(C)C2=CC=CC=C2N(CCCCCCCCCCCCCCCCCC)C1=CC=CC1=[N+](CCCCCCCCCCCCCCCCCC)C2=CC=CC=C2C1(C)C JVXZRNYCRFIEGV-UHFFFAOYSA-M 0.000 claims 1
- 239000002245 particle Substances 0.000 description 238
- 241000283074 Equus asinus Species 0.000 description 105
- 230000008685 targeting Effects 0.000 description 74
- 241001465754 Metazoa Species 0.000 description 54
- 238000002604 ultrasonography Methods 0.000 description 50
- 210000001519 tissue Anatomy 0.000 description 38
- 210000002216 heart Anatomy 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 29
- 210000004165 myocardium Anatomy 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 28
- 239000002158 endotoxin Substances 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 28
- 239000002953 phosphate buffered saline Substances 0.000 description 28
- 150000002632 lipids Chemical class 0.000 description 27
- 229920006008 lipopolysaccharide Polymers 0.000 description 26
- 101100401100 Caenorhabditis elegans mes-1 gene Proteins 0.000 description 24
- 238000001727 in vivo Methods 0.000 description 23
- 230000027455 binding Effects 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 239000012634 fragment Substances 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 16
- 239000000872 buffer Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 238000002156 mixing Methods 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000013642 negative control Substances 0.000 description 12
- 238000011002 quantification Methods 0.000 description 12
- 210000000264 venule Anatomy 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 230000003511 endothelial effect Effects 0.000 description 11
- 210000000265 leukocyte Anatomy 0.000 description 11
- 238000000527 sonication Methods 0.000 description 11
- 208000007536 Thrombosis Diseases 0.000 description 10
- 238000013019 agitation Methods 0.000 description 10
- 238000000799 fluorescence microscopy Methods 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 208000028867 ischemia Diseases 0.000 description 9
- 230000014759 maintenance of location Effects 0.000 description 9
- 238000000386 microscopy Methods 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102000018697 Membrane Proteins Human genes 0.000 description 8
- 108010052285 Membrane Proteins Proteins 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 102000023732 binding proteins Human genes 0.000 description 8
- 108091008324 binding proteins Proteins 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 238000004108 freeze drying Methods 0.000 description 8
- 238000003364 immunohistochemistry Methods 0.000 description 8
- 238000012771 intravital microscopy Methods 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 230000007935 neutral effect Effects 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000004624 confocal microscopy Methods 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 230000009871 nonspecific binding Effects 0.000 description 7
- 238000002203 pretreatment Methods 0.000 description 7
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000007900 aqueous suspension Substances 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 238000002591 computed tomography Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000008030 elimination Effects 0.000 description 6
- 238000003379 elimination reaction Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000007654 immersion Methods 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 229920002477 rna polymer Polymers 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- 230000003068 static effect Effects 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 5
- 239000012099 Alexa Fluor family Substances 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 230000002349 favourable effect Effects 0.000 description 5
- 238000005188 flotation Methods 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 150000003839 salts Chemical group 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 150000003573 thiols Chemical class 0.000 description 5
- 238000010200 validation analysis Methods 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 101001116301 Mus musculus Platelet endothelial cell adhesion molecule Proteins 0.000 description 4
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 4
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 4
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 4
- 241000183024 Populus tremula Species 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000005030 aluminium foil Substances 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000000339 bright-field microscopy Methods 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940014144 folate Drugs 0.000 description 4
- 239000011724 folic acid Substances 0.000 description 4
- RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000002688 persistence Effects 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 238000002600 positron emission tomography Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 4
- 229960001600 xylazine Drugs 0.000 description 4
- XFKSLINPMJIYFX-UHFFFAOYSA-N 1-sulfanylpyrrole-2,5-dione Chemical compound SN1C(=O)C=CC1=O XFKSLINPMJIYFX-UHFFFAOYSA-N 0.000 description 3
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- 108010024212 E-Selectin Proteins 0.000 description 3
- 102100023471 E-selectin Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010019315 Heart transplant rejection Diseases 0.000 description 3
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 3
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000005415 bioluminescence Methods 0.000 description 3
- 230000029918 bioluminescence Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 210000005242 cardiac chamber Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002594 fluoroscopy Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229960003299 ketamine Drugs 0.000 description 3
- 230000002045 lasting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 210000004197 pelvis Anatomy 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 229960001153 serine Drugs 0.000 description 3
- 238000002603 single-photon emission computed tomography Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229910052688 Gadolinium Inorganic materials 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 2
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- 102100028793 Mucosal addressin cell adhesion molecule 1 Human genes 0.000 description 2
- 101710139349 Mucosal addressin cell adhesion molecule 1 Proteins 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-BJUDXGSMSA-N Nitrogen-13 Chemical compound [13N] QJGQUHMNIGDVPM-BJUDXGSMSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- SFKMOQVNCIESJL-UHFFFAOYSA-N dibromo(difluoro)methane;1,1-dichloro-1,2,2,2-tetrafluoroethane Chemical compound FC(F)(Br)Br.FC(F)(F)C(F)(Cl)Cl SFKMOQVNCIESJL-UHFFFAOYSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 125000005313 fatty acid group Chemical group 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-BJUDXGSMSA-N fluorine-18 atom Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000013105 post hoc analysis Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000005245 right atrium Anatomy 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940056501 technetium 99m Drugs 0.000 description 2
- 210000001631 vena cava inferior Anatomy 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- FGMHFEDLKOSOSW-UHFFFAOYSA-N 2-[di(hexadecanoyl)amino]ethyl dihydrogen phosphate Chemical compound C(CCCCCCCCCCCCCCC)(=O)N(CCOP(=O)(O)O)C(CCCCCCCCCCCCCCC)=O FGMHFEDLKOSOSW-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- 125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- NJYVEMPWNAYQQN-UHFFFAOYSA-N 5-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21 NJYVEMPWNAYQQN-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 229910001312 Amalgam (dentistry) Inorganic materials 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000003072 Ellman's test Methods 0.000 description 1
- 102000012085 Endoglin Human genes 0.000 description 1
- 108010036395 Endoglin Proteins 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical class C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- IGLNJRXAVVLDKE-OIOBTWANSA-N Rubidium-82 Chemical compound [82Rb] IGLNJRXAVVLDKE-OIOBTWANSA-N 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 241001116459 Sequoia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- FHNFHKCVQCLJFQ-NJFSPNSNSA-N Xenon-133 Chemical compound [133Xe] FHNFHKCVQCLJFQ-NJFSPNSNSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 201000008562 aortic malignant tumor Diseases 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 239000000448 dental amalgam Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- GFZPJHFJZGRWMQ-UHFFFAOYSA-M diOC18(3) dye Chemical compound [O-]Cl(=O)(=O)=O.O1C2=CC=CC=C2[N+](CCCCCCCCCCCCCCCCCC)=C1C=CC=C1N(CCCCCCCCCCCCCCCCCC)C2=CC=CC=C2O1 GFZPJHFJZGRWMQ-UHFFFAOYSA-M 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000005066 dodecenyl group Chemical group C(=CCCCCCCCCCC)* 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002169 extracardiac Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical group C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 229940006110 gallium-67 Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 229940039412 ketalar Drugs 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- DNNSSWSSYDEUBZ-OIOBTWANSA-N krypton (81mKr) gas Chemical compound [81Kr] DNNSSWSSYDEUBZ-OIOBTWANSA-N 0.000 description 1
- 229960001299 krypton (81mkr) gas Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000005248 left atrial appendage Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 108010039221 lysyl-glutaminyl-alanyl-glycyl-aspartyl-valine Proteins 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000001802 myricyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960005419 nitrogen Drugs 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- LYRFLYHAGKPMFH-UHFFFAOYSA-N octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(N)=O LYRFLYHAGKPMFH-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-BJUDXGSMSA-N oxygen-15 atom Chemical compound [15O] QVGXLLKOCUKJST-BJUDXGSMSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 125000005471 saturated fatty acid group Chemical group 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000002060 skeletal muscle cancer Diseases 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- BKVIYDNLLOSFOA-OIOBTWANSA-N thallium-201 Chemical compound [201Tl] BKVIYDNLLOSFOA-OIOBTWANSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000005040 tridecenyl group Chemical group C(=CCCCCCCCCCCC)* 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 125000005065 undecenyl group Chemical group C(=CCCCCCCCCC)* 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 229940106670 xenon-133 Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
- A61K49/0082—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion micelle, e.g. phospholipidic micelle and polymeric micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
- A61K49/1809—Micelles, e.g. phospholipidic or polymeric micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
Definitions
- the present invention relates to microparticle compositions.
- it concerns microparticle compositions suitable for ultrasound imaging of chosen molecular moieties.
- Diagnostic sonography is an ultrasound-based diagnostic imaging technique used for visualising tissues including tendons, muscles, joints, vessels and internal organs for possible pathology or lesions.
- a common example is obstetric sonography, which is routinely used during pregnancy.
- ultrasound imaging has been limited to defining anatomical structure and movement, and blood flow.
- Ultrasound molecular imaging facilitates imaging of a given molecular moiety/moieties of interest (expressions) by way of targeting microbubbles, which comprise targeting ligands (molecular binding elements) on the particle shell. 1
- This method works by intravenous (iv) administration of the targeting microbubbles, which then circulate and accumulate in regions expressing the molecules of interest. Accumulation of the microbubbles may be depicted on an ultrasound image as areas of bright signal locating the molecules.
- microparticle composition which is non-immunogenic, and thus suitable for use in the ultrasound molecular imaging of human subjects as well as animals. Furthermore, it is an aim to provide a microparticle composition which is specific and effective in vivo for highly quantitative and real-time ultrasound molecular imaging of molecular moieties of interest in one or more tissues/organs.
- microparticles so produced may have one or more favourable characteristics in vivo which include, but are not limited to, being non-toxic, sufficiently stable for continuous and/or multi-plane imaging with a single-bolus microparticle administration, having favourable kinetics and acoustic response for highly quantitative analysis of the molecular moieties of interest, a sufficiently high targeting specificity and efficiency to the molecular moieties of interest, and lacking non-specific binding/persistence in tissues not expressing the molecular moieties (target molecules) of interest (except in tissues of the reticuloendothelial system (RES) such as the liver and spleen which are the usual routes of microparticle elimination in the body).
- RES reticuloendothelial system
- a microparticle composition suitable for molecular imaging comprising microparticles, wherein the microparticles comprise: a core microparticle structure having a central area and a shell, and wherein the core microparticle structure comprises: (i) a phosphatidylcholine lipid; (ii) a phosphatidylethanolamine lipid comprising at least one maleimide moiety; and (iii) an alkoxylated fatty acid.
- This composition provides a native microparticle structure which can be modified as appropriate for imaging of a selected molecular target(s) (molecular moiety/moieties of interest).
- the microparticles may further comprise at least one molecular binding element, wherein the at least one molecular binding element is covalently attached to the shell of the core microparticle structure.
- the specific composition has been found to yield sufficiently echogenic and stable microparticles, which lack non-specific binding, and produce no immediate adverse effects in vivo.
- the microparticles also facilitate efficient target binding under flow conditions by means of the molecular binding element(s) attached to the shell of the core structure. Favourable kinetics and acoustic response of the microparticles allow highly quantitative real-time ultrasound molecular imaging in vivo.
- molecular imaging refers to the imaging of molecular moieties, such as, but not limited to, molecules, cells, or particles (including those present on artificial/implanted materials, e.g., metals, polymers or drugs on a coronary stent, prosthetic heart valve or closure device).
- molecular imaging may be used to refer to the imaging of phenotypes (detecting the presence, absence, and/or degree of), by targeting one or a combination of the molecular moieties with the microparticles.
- phenotypes include, but are not limited to, the physiological state, pathological state, pathophysiological state, disease state, or operational state (e.g., of a device).
- microparticles targeting E-selectin can be used for imaging detection and assessment of the degree of Esel expression, as well as endothelial activation and/or inflammation.
- E-selectin an endothelial adhesion molecule expressed during endothelial activation in inflammation
- Non-targeting microparticles such as microparticles containing irrelevant molecular binding elements, or none at all, may be used in molecular imaging, often as negative controls or for assessing the degree of non-specific microparticle binding/adhesion/retention in the tissue/organ/subject/system, or as agents for calibration of imaging signals (e.g., calibration of microparticle ultrasound imaging signal intensity vs. microparticle concentration), or for assessing perfusion or delineating blood-tissue boundary, etc.
- imaging signals e.g., calibration of microparticle ultrasound imaging signal intensity vs. microparticle concentration
- microparticle refers to small particles which behave as a whole unit in terms of their transport and properties, and which typically exhibit an average particle size diameter (determined, for example, by a microscopy, electrozone sensing, or laser diffraction technique) in the range of 0.1 to 10 ⁇ (preferably 1 to 5 ⁇ ).
- microbubble may be used synonymously with the term "microparticle”.
- a liposome is an exemplary type of microparticle which may be considered as an artificially-prepared vesicle composed of a lipid bilayer.
- a micelle is a type of microparticle which may be considered as an artificially- prepared particle composed of a hydrophilic shell and a hydrophobic centre.
- the microparticles of the invention comprise a core microparticle structure having a central area and a shell.
- the core microparticle structure is made up of a predominantly lipid-based composition, which comprises (i) a phosphatidylcholine lipid; (ii) a phosphatidylethanolamine lipid comprising at least one maleimide moiety; and (iii) an alkoxylated fatty acid. These components readily self-assemble to form a stable microparticle core structure.
- the phosphatidylcholine and phosphatidylethanolamine lipids of the invention are typically neutral phospholipids. As such, they are lipids comprising a hydrophilic head group comprising a phosphate group, and a hydrophobic tail group.
- neutral refers to an entity that resides in an uncharged or neutral zwitterionic form at a selected pH.
- a suitable pH may, for example, be 7.4 +/- 0.5.
- the phosphatidylcholine and phosphatidylethanolamine lipids of the invention typically possess a hydrophobic tail group adorning the hydrophilic head group which is saturated or unsaturated.
- the hydrophilic tail groups are saturated fatty acid groups or derivatives thereof.
- fatty acid refers to linear or branched, saturated or unsaturated carboxylic acids or derivatives thereof comprising a carbon chain of C 7 _2 4 .
- saturated fatty acids comprise a carbon chain of Cio-24, or more preferably Cio-20-
- the phosphatidylcholine lipid of component (i) is preferably a phosphatidylcholine lipid comprising fatty acid chains of C 7 _ 24 , more preferably C 8 _22, most preferably Qo-20- Specific examples of such lipids include, for example, dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), palmitoyloleoylphosphatidylcholine (POPC), and distearoylphosphatidylcholine (DSPC).
- DOPC dioleoylphosphatidylcholine
- DPPC dipalmitoylphosphatidylcholine
- POPC palmitoyloleoylphosphatidylcholine
- DSPC distearoylphosphatidylcholine
- the phosphatidylcholine lipid of component (i) is a saturated C 10-20 phosphatidylcholine lipid, such as distearoylphosphatidylcholine (DSPC; l,2-distearoyl-sn-glycero-3-phosphocholine).
- DSPC distearoylphosphatidylcholine
- l,2-distearoyl-sn-glycero-3-phosphocholine is a saturated C 10-20 phosphatidylcholine lipid, such as distearoylphosphatidylcholine (DSPC; l,2-distearoyl-sn-glycero-3-phosphocholine).
- the phosphatidylethanolamine lipid of component (ii) preferably comprises a phosphatidylethanolamine lipid comprising fatty acid chains of C 7 _2 4 , more preferably C 8 _22, most preferably C 10-20 ⁇
- Such lipids include structures based on, for example, dioleoyl phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylethanolamine (POPE), and distearoylphosphatidylethanolamine (DSPE).
- DOPE dioleoyl phosphatidylethanolamine
- POPE palmitoyloleoylphosphatidylethanolamine
- DSPE distearoylphosphatidylethanolamine
- the phosphatidylethanolamine lipid of component (ii) is a saturated C 10-20 phosphatidylethanolamine lipid, such as one comprising distearoylphosphatidylethanolamine (DSPE).
- the phosphatidylethanolamine lipid of component (ii) is pegylated.
- the term "PEGylated” refers to an entity, typically a polymer- or lipid-based entity, which is covalently attached to a polyethylene glycol (PEG) polymer chain.
- the PEG chain has a molecular formula of C 2 nH 4n+2 0 n+ i and a molecular mass of less than 20,000 g/mole.
- the maleimide moiety may be attached to the PEG polymer chain, more preferably the PEG polymer chain provides a covalent linkage between the maleimide moiety and the phosphatidylethanolamine lipid portion.
- the phosphatidylethanolamine lipid of component (ii) preferably comprises a polyethylene glycol chain with a molecular weight of at least 500, such as at least 1000, 1500, or 2000.
- a polyethylene glycol chain with a molecular weight of between 1500 and 2500 is preferred.
- the phosphatidylethanolamine lipid of component (ii) comprises at least one maleimide moiety.
- a maleimide moiety is a chemical entity with the general formula H 2 C 2 (CO) 2 NH, which may be represented by the following structure.
- the NH group of the maleimide moiety of component (ii) is covalently attached to the phosphatidylethanolamine portion, potentially via the PEG polymer chain.
- a particularly preferred phosphatidylethanolamine lipid of the microparticle composition is 1,2- distearoyl-5n-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (abbreviated as DSPE-PEG 20 oo-Mal).
- a maleimide moiety as a handle for the molecular binding element is a departure from the immunogenic (strept)avidin-biotin conjugation chemistry traditionally used in preparing such particles.
- immunogenic (strept)avidin-biotin conjugation chemistry traditionally used in preparing such particles.
- other conjugation chemistries may be used, it was surprisingly found that a maleimide linker yields microparticles with a low level of immunogenicity.
- the pH stability of the maleimide linkage was found to be advantageous in terms of avoiding degradation of the molecular binding element(s), and thus the microparticles during preparation, and by preventing dissociation of the molecular binding element(s) from the microparticle shell in vivo.
- the alkoxylated fatty acid according to component (iii) of the invention may comprise a fatty acid group which is linear or branched, saturated or unsaturated.
- the fatty acid chain may be a C 7 _ 24 , more preferably a C 8 _ 2 2, most preferably a C 10-20 chain.
- fatty acid chains comprising linear, saturated or unsaturated (preferably saturated) C 10-20 chain are preferred.
- the alkoxy group i.e.
- the group that forms an ester with the fatty acid group may be a linear or branched alkyl group (preferably C 1-5 o alkyl or C 1-24 alkyl), alkenyl group (preferably Ci_5o alkenyl or Ci_ 24 alkenyl), or polyethylene glycol group, singularly bonded to the oxygen of the fatty acid.
- Ci-50 alkyl refers to a linear or branched saturated hydrocarbon group containing from 1 to 50 carbon atoms.
- Ci-50 alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n- pentyl, isopentyl, neopentyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3- dimethylbutyl, 2-ethylbutyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, myristyl, palmityl, stearyl, icosyl, triacontyl, tetracontyl, and pentacontyl.
- Ci_so alkenyl groups include ethenyl, 1-propenyl, 2-propenyl, 2-methyl-l-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4- pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 3-hexenyl, 5-hexenyl, heptenyl, octenyl, nonenyl, decenyl, undecenyl, dodecenyl, tridecenyl, pentadecenyl, and hexedecenyl.
- hydrocarbon' refers to an entity which consists of hydrogen and carbon only. Such an entity may be saturated or unsaturated, branched or linear.
- the alkoxylated fatty acid is a polyethylene glycol fatty acid.
- a suitable alkoxylated fatty acid may be, for example, a C 10-20 saturated polyethylene glycol fatty acid ester.
- a particularly preferred polyethylene glycol fatty acid ester is PEG 4 o stearate.
- components (i)-(iii) or any further components mentioned herein may be present in salt form as well as in free (acid or base) form.
- the microparticle composition according to the invention may comprise at least one molecular binding element covalently attached to the shell of the core microparticle structure.
- a targeting microparticle is produced which is specific to a chosen molecular moiety (expression), e.g., attaches specifically to a chosen molecular moiety.
- the at least one molecular binding element is covalently attached to the core microparticle structure via the at least one maleimide moiety.
- the microparticle composition may comprise one or more different molecular binding elements in order to target one or more molecular moieties (expressions).
- the molecular binding element may be any inorganic or organic molecule which is capable of binding to a complementary molecular moiety.
- the precise identity and nature of the molecular binding element will depend on the molecular moiety of interest which is to be recognised by the microparticles and imaged.
- the molecular moiety may be a molecule, protein, receptor, particle or cell, including those present on an artificial or implanted material.
- the molecular moiety may be present on the surface of cells.
- the molecular binding element can be any suitable element which is capable of binding to the molecular moiety of interest.
- the molecular binding element should bind specifically to the molecular moiety of interest so that it does not bind to other molecular moieties.
- Suitable molecular binding elements may therefore comprise, but not limited to, proteins, peptides, nucleic acids, carbohydrates, lipids, inorganic moieties, or small organic moieties (e.g. drug molecules).
- the molecular binding moiety may be a metal (e.g., ions of nickel, cobalt, manganese or zinc, which bind to histidine-tag).
- the molecular binding element may be a binding protein, an affibody, or an antibody molecule.
- binding protein refers to any protein capable of binding specifically to a molecule (hereinafter called its "binding partner").
- a specific binding protein has a binding site at which it binds to its binding partner.
- the binding protein generally only binds with high affinity at this site to its binding partner and other molecules with a very similar structure to its binding partner. Molecules that are not similar to the binding partner will be bound with low affinity, if at all.
- Binding proteins are well known to those skilled in the art. Examples of binding proteins include but are not limited to T-cell receptors, HLA proteins, cell surface receptors and enzymes. 5
- binding protein also includes a functional fragment of these or any other molecules that is capable of specific binding. A functional fragment is a part of the binding protein which is still able to bind its binding partner specifically with high affinity.
- antibody refers to a small molecule based on a 58 amino acid residue protein domain, derived from one of the IgG-binding domains of staphylococcal protein A. These can be selected to have specific affinity for a small molecule (see, for example, patent reference WO 95/19274 AD. 6"8
- antibody refers to polyclonal or monoclonal antibodies of any isotype, or antigen binding fragments thereof, such as Fv, Fab, F(ab') 2 fragments and single chain Fv fragments.
- the antibody molecule may be a recombinant antibody molecule, such as a chimeric antibody molecule, a CDR grafted antibody molecule (also known as a humanised antibody molecule) or a fragment thereof.
- Such antibodies and methods for their production are well known in the art.
- the antibody molecule can be produced in any suitable manner, e.g. using hybridomas or phage technology. One skilled in the art would know how to produce an antibody having specific binding affinity to the small molecule.
- the antibody molecule can be produced from any suitable organism, for example, from sheep, mice, rabbits, goats, donkeys, camels, lamas or sharks.
- the antibody molecules are human, humanised, chimeric or rodent antibody molecules.
- the term "bind specifically" refers to an interaction between two molecules which forms a complex that is relatively stable under physiological conditions. It is characterised by a high affinity as distinguished from non-specific binding which usually has a low affinity.
- the molecular binding element is preferably an antibody molecule.
- the antibody molecule may be covalently attached to the maleimide group by means of a pendant thiol group (e.g. -SH), thereby creating a thioether linkage (e.g. -S-).
- Esel is an antibody for E-selectin (Esel).
- Esel is an endothelial adhesion molecule, classically expressed only on activated endothelial cells (basal expression in resting endothelial cells is lacking). 9 In particular, it can be used for the specific detection of endothelial activation or inflammation. 10 ' 11 As such, one embodiment of the present invention has allowed the specific imaging of Esel in the heart and kidneys for the first time using ultrasound.
- intravascular molecules/cells which are involved in various pathophysiological processes of different diseases and which can be the target of the molecular binding element include, but are not limited to:
- P-selectin P-selectin
- selectins non-selectively i.e. combination of Esel, Psel, Lsel non- selectively
- ICM-1 inter-cellular adhesion molecule- 1
- VCAM-1 vascular cell adhesion molecule-1
- MAdCAM-1 mucosal addressin cell adhesion molecule-1
- Pi,P3-containing integrin e.g., asPi, ⁇ ⁇ ⁇ 3 , (3 ⁇ 43 ⁇ 4 ⁇ 3 (glycoprotein Ilb/IIIa receptor (GPIIb/IIIa receptor))
- GPIIb/IIIa receptor GPIIb/IIIa receptor
- Vascular endothelial growth factor receptor-2 (VEGFR2), ⁇ , ⁇ 3 - or a v - containing integrins (e.g., ⁇ 5 ⁇ , ⁇ ⁇ ⁇ 3 ) and endoglin in the angiogenesis of: (a) tumour (breast, prostate, ovarian, colon, pancreatic cancer, melanoma, angiosarcoma, fibrosarcoma and glioma) located in the brain, pancreas, mammary fat pad, hind limb, flanks or inguinal area; (b) chronic ischaemia (hind limb skeletal muscle); and (c) matrigel plug angiogenesis.
- tumour (breast, prostate, ovarian, colon, pancreatic cancer, melanoma, angiosarcoma, fibrosarcoma and glioma) located in the brain, pancreas, mammary fat pad, hind limb, flanks or inguinal area; (
- L-selectin (Lsel) in lymph nodes (iv) L-selectin (Lsel) in lymph nodes.
- Reporter molecules such as the major histocompatibility complex (MHC) class I H-2Kk protein on, for example, transfected bone-marrow derived endothelial progenitor cells in endothelial progenitor cell therapy.
- MHC major histocompatibility complex
- Activated leukocytes such as in ischaemia-reperfusion injury, acute myocardial infarction & primary angioplasty, and heart transplant rejection in the heart or kidneys (phosphatidyl serine may be used as a molecular binding element to target activated leukocytes through possible mechanisms including, but not limited to, charge interaction and binding through complement)
- the molecular binding element may be selected from the following table.
- Glycoprotein Peptide linear Thrombosis Inferior vena cava Takeuchi M et al,
- Phosphatidylserine interaction with leukocyte includes charge interaction and complement receptor(s) (undefined) on activated leukocytes, c. Actual molecular target unknown.
- any maleimide moieties i.e. those containing active maleimide function
- any maleimide moieties may be deactivated by, for example, hydrolysis or by reaction with excess thiols.
- the conjugation reaction ratio used in the conjugation reaction is preferably at least 2 x 10 6 molecular binding elements (e.g. antibody molecules) per microparticle. In some embodiments, the conjugation reaction ratio may be at least 3 x 10 6 molecular binding elements per microparticle. Further, the conjugation reaction ratio may be at least 4 x 10 6 molecular binding elements per microparticle. When using reaction ratios of this order, microparticles are produced which are able to sufficiently bind under flow conditions as well as static conditions. Lower levels (e.g. approximately lxlO 6 molecular binding elements per particle) produce microparticles which are only able to target under static conditions.
- the conjugation reaction ratio used in the reaction to conjugate the molecular binding element to the microparticle is such that the conjugation reaction molar ratio of the at least one molecular binding element to component (ii) is >1:1. Otherwise, the conjugation reaction molar ratio of the at least one molecular binding element to component (ii) may be >5: 1. Further, the conjugation reaction molar ratio may be >8:1, >9: 1, or >10: 1. In some embodiments, the conjugation reaction molar ratio may be about 10: 1.
- the microparticles have at least about 0.3 x 10 5 molecular binding elements (e.g. antibody molecules) per microparticle. This allows the microparticles to be able to sufficiently bind under flow conditions as well as static conditions.
- the microparticles have at least about 1 x 10 5 molecular binding elements (e.g. antibody molecules) per microparticle.
- the microparticles may have at least about 2 x 10 5 molecular binding elements (e.g. antibody molecules) per microparticle.
- the microparticles may have at least about 3 x 10 5 molecular binding elements (e.g. antibody molecules) per microparticle.
- the microparticles may have between about 3 x 10 5 and about 4 x 10 5 molecular binding elements (e.g. antibody molecules) per microparticle.
- the microparticles may have at least about 2500 conjugated molecular binding elements (e.g. antibody molecules) per ⁇ microparticle surface area. Further, the microparticles may have at least about 5000 conjugated molecular binding elements (e.g. antibody molecules) per ⁇ microparticle surface area. In some embodiments, the microparticles may have at least about 7500 conjugated molecular binding elements (e.g. antibody molecules) per ⁇ microparticle surface area. It has been found that by keeping the conjugation sites on each molecular binding element to a minimum (e.g. reducing only 1 interchain disulfide bond to produce 2 -SH groups per antibody), and deactivating any unreacted groups after particle conjugation (e.g. by alkylation of unreacted -SH groups), significant particle aggregation due to cross-linking could be avoided.
- a minimum e.g. reducing only 1 interchain disulfide bond to produce 2 -SH groups per antibody
- deactivating any unreacted groups after particle conjugation
- the molecular binding element may be covalently attached to the component (ii) of the microparticle composition either before or after formation of the microparticles.
- the molar ratio of the resulting component is 5 to 15.
- the structural morphology of the microparticles is not limited in any way and the particles may exhibit a liposomal or micellar structure.
- the core microparticle structure is micellar.
- hydrophilic head groups of the constituent lipids create the shell of the core structure, while hydrophobic tails extend inward to the central area of the core.
- the core microparticle structure is liposomal.
- the microparticle composition contains a fluid medium in the central area of the core microparticle structure.
- the fluid medium may be any physiologically acceptable medium, which may or may not contain active ingredients for delivery to the locations specifically targeted by the molecular binding element.
- the fluid medium comprises a physiologically acceptable gas.
- Suitable physiologically acceptable gases include air, nitrogen, carbon dioxide, xenon, krypton, sulfur hexafluoride, chlorotrifluoromethane, dichlorodifluoro-methane, bromotrifluoromethane, bromochlorodifluoromethane, tetrafluoromethane, dibromo-difluoromethane, dichlorotetrafluoroethane, chloropentafluoroethane, hexafluoroethane, hexafluoropropylene, octafluoropropane, hexafluoro-butadiene, octafluoro-2-butene, octafluorocyclobutane, decafluorobutane, perfluorocyclopentane, dodecafluoropentane, and tetradecafluorohexane.
- the physiologically acceptable gas is selected from air, nitrogen, sulfur hexafluoride, octafluoropropane, decafluorobutane, dodecafluoropentane, and tetradecafluorohexane.
- the physiologically acceptable gas may be selected from sulfur hexafluoride, chlorotrifluoromethane, dichlorodifluoro-methane, bromotrifluoromethane, bromochlorodifluoromethane, tetrafluoromethane, dibromo- difluoromethane, dichlorotetrafluoroethane, chloropentafluoroethane, hexafluoroethane, hexafluoropropylene, octafluoropropane, decafluorobutane, dodecafluoropentane, and tetradecafluorohexane.
- the physiologically acceptable gas may be selected from sulfur hexafluoride, octafluoropropane, decafluorobutane, dodecafluoropentane, and tetradecafluorohexane.
- the physiologically acceptable gas is octafluoroprop ane .
- the microparticles may have an average diameter (as determined, for example, by microscopy, electrozone sensing, or laser diffraction techniques) in the range of 0.1 to 10 ⁇ , 0.2 to 10 ⁇ or 0.5 to 10 ⁇ . In some embodiments, the microparticles may have an average diameter in the range of 0.5 to 8 ⁇ , 0.5 to 7 ⁇ or 0.8 to 6 ⁇ . In particular embodiments, the microparticles may have an average diameter in the range of 1 to 5 ⁇ . The microparticles may possess a predominately spherical morphology. In addition, the particle size distribution may be such that at least 90% or at least 95% of the particles are under 10 ⁇ (preferably under 6 ⁇ ) in diameter.
- all the microparticles will have a diameter of less than ⁇ . In further embodiments, at least 95% of the microparticles will have a diameter of less than 6 ⁇ .
- Microparticles of this size can traverse through the microvasculature or microcirculation, including the pulmonary capillary bed, unimpeded when administered for example systemically (e.g. iv).
- the particles may have a near neutral charge, zeta potential in the range >-30mV to ⁇ +30mV, when measured with/without purification of the microparticles from their unincorporated shell components.
- the zeta potential may preferably be in the range >-20mV to ⁇ +20mV, more preferably >-20mV to ⁇ +10mV.
- a specific example of a microparticle comprising an antibody as the molecular binding element has a zeta potential of approximately 5mV in ImM KC1 at pH 7.4.
- Microparticles may be administered via any suitable route, examples include, but are not limited to, iv, intra-arterial, intramuscular, intra-lymphatic, or direct injection/administration into tissue or tissue cavity/space.
- the microparticles possess a composition in which the molar ratio of (i) to (iii) satisfies the following ranges: (i) 70 to 80; (ii) 5 to 15; and (iii) 10 to 20.
- a targeting microparticle may be produced which is functional and viable in vivo (particularly humans) for effective, quantitative and real-time ultrasound molecular imaging.
- the composition of the microparticles may be used synonymously with the composition of the component mixture used to generate the microparticles (e.g., an intermediate microparticle composition).
- the microparticle formulation may also comprise one or more labelling moieties, or pharmaceutically acceptable salts thereof.
- a labelling moiety is an entity which aids the visualisation of the microparticles by imaging techniques.
- the molar ratio of the labelling moiety in the composition may be 0.2 to 50, preferably 0.5 to 5.
- One example of a labelling moiety is a fluorescent dye, which can be used as a visualisation tool.
- fluorescent dyes include, but are not limited to, l,2-dioleoyl-sn-glycero-3- phosphoethanolamine- V-(5- dimethylamino-l-naphthalenesulfonyl, l,2-dioleoyl-sn-glycero-3- phosphoethanolamine-N-(l-pyrenesulfonyl), l,2-dioleoyl-sn-glycero-3-phosphoethanolamine- V- (carboxyfluorescein) , 1 -oleoyl-2- [6- [(7-nitro-2-l,3 -benzoxadiazol-4-yl)amino]hexanoyl] - sn- glycero-3-phospho-L-Serine, 25-[N-[(7-nitrobenz-2-oxa-l,3-diazol-4-yl)-methyl]amino]-27- norcholesterol,
- a preferred fluorescent dye is l,l'-dioctadecyl- 3,3,3',3'-tetramethylindocarbocyanine perchlorate (Dil).
- the molar ratio of the fluorescent dye in the composition may be 0.5 to 5, preferably 1 to 4, even more preferably 1.5 to 3.
- the microparticle composition may comprise more than one fluorescent dye.
- the labelling moieties may be incorporated in the microparticle composition via attachment to one or more of components (i), (ii), or (iii), a molecular binding element, or an additional component (e.g., another lipid component).
- the labelling moiety is added via an existing microparticle component(s)
- the molar ratio of the unlabelled component(s) e.g., component (i), (ii), (iii), or the conjugation ratio of the molecular binding element
- the molar ratio of the unlabelled component(s) may remain unchanged or reduced proportionately so that the sum molar ratio of a particular component(s) with label plus without label remains unchanged.
- the final component composition can either comprise DSPC-FITC/DSPC/DSPE-PEG 20 oo- al/PEG 40 stearate at a molar ratio 2/75/9/14 or 2/73/9/14.
- the label is added via an additional component (e.g., via DSPE as another lipid)
- the molar ratio of the other microparticle components may remain unchanged.
- the final component composition may then comprise D1I/DSPC/DSPE-PEG 2 000- Mal/PEG 4 o stearate at a molar ratio of 2/75/9/14. More than one type of labelling moiety may be used for a given microparticle, using the same principles above.
- Alternative labelling moieties include those known in the art for use in various imaging techniques, such as magnetic resonance imaging (MRI), scintigraphy, single photon emission computed tomography (SPECT), positron emission tomography (PET), computed tomography (CT), X-ray imaging/fluoroscopy, fluorescence imaging, bioluminescence imaging, microscopy, optical methods, ultrasound imaging, or multi-modal variants thereof.
- MRI magnetic resonance imaging
- SPECT single photon emission computed tomography
- PET positron emission tomography
- CT computed tomography
- labelling moieties may include, but are not limited to, paramagnetic, superparamagnetic or ultrasuperparamagnetic particles (e.g., gadolinium (Gd), iron oxide, iron, platinum, manganese), radionuclides (e.g., technetium-99m, thallium-201, iodine-123, iodine-131, gallium-67, indium- I l l, fluorine-18, carbon- 11, nitrogen-13, oxygen- 15, rubidium-82), radio-opaque particles (e.g., iodine, barium, metal), fluorophores or fluorescent dye (e.g., those mentioned above), enzyme substrates (e.g., that for luciferase), and gold nanoparticles.
- paramagnetic, superparamagnetic or ultrasuperparamagnetic particles e.g., gadolinium (Gd), iron oxide, iron, platinum, manganese
- radionuclides e.g.
- labels may include, but are not limited to, Gd-DTPA-bis(stearylamide) (Gd-BSA); Gd-DTPA- bis(myrisitylamide) (GdDTPA-BMA); l,2-dimyristoyl-sn-glycero-3- phosphoethanolaminediethylene-triaminepentaacetate: Gd3+ (DMPEDTPA:Gd3+); D35-1.2- dihexanoyl-sn-glycero-3-phosphocholine; gadolinium (III) 2-[4,7-bis-carboxymethyl-10-[(N,N- distearylamidomethyl-N"-amido-methyl]-l,4,7, 10-tetra-azacyclododec- l-yl]-acetic acid (Gd.DOTA.DSA); gadolinium (III) 1,4,7, 10-tetraazacyclododecane-l,4,7, 10-tetraacetic acid mono(N
- labelling moieties may be introduced into the microparticles via microparticle components (i), (ii), or (iii), a molecular binding element, or via an additional component (e.g., another lipid component).
- a labelling moiety is added via an existing microparticle component(s)
- the molar ratio of the unlabelled component(s) e.g., component (i), (ii), (iii), or the conjugation ratio of the molecular binding elements
- the conjugation ratio of the molecular binding elements may remain unchanged or reduced proportionately so that the sum molar ratio of a particular component(s) with label plus without label remains unchanged.
- a Gd label is introduced via component (i) as Gd.DOTA.DSPC at molar ratio of 20 to a component composition comprising DSPC/DSPE-PEG 2 ooo-Mal/PEG 4 o stearate at molar ratio of 75/9/14
- the final component composition can either comprise Gd.DOTA.DSPC/DSPC/DSPE-PEG 20 oo- al/PEG 40 stearate at molar ratio 20/75/9/14 or 20/55/9/14.
- the molar ratio of the other microparticle components may remain unchanged.
- the final component composition may then comprise Gd.DOTA.DSPE/DSPC/DSPE-PEG 20 oo- al/PEG 40 stearate at molar ratio 20/75/9/14/2.
- the label forms a minor molar content of the overall microparticle formulation, but in sufficient quantities commensurate with the detection sensitivity of the intended imaging method(s). For example, more gadolinium label would be needed for MRI detection than fluorine- 18 label for PET detection or Dil label for fluorescence microscopy detection. More than one type of label may be used for a given microparticle, using the same principles above.
- the microparticle formulation may also comprise a further lipid component such as distearoylphosphatidylethanolamine (DSPE).
- DSPE distearoylphosphatidylethanolamine
- the molar ratio of DSPE in the composition may be 0.5 to 5, preferably 1 to 4, even more preferably 1.5 to 3.
- a label e.g., a fluorescent dye such as Dil
- a label e.g., a fluorescent dye such as Dil
- the microparticle formulation may further comprise a tumour targeting agent.
- a tumour targeting agent typically comprise a ligand for a receptor that is over-expressed in tumour cells relative to the expression of said receptors in the cells of non-tumourous tissue of mammals.
- the molecular binding element is a tumour targeting agent.
- a tumour targeting agent is one which comprises a folate moiety.
- the tumour targeting agent is a phospholipid- polyethylene glycol-folate compound. More preferably the phospholipid-poly ethylene glycol- folate compound is DSPE-PEG2ooo-Folate [distearoylphosphatidylethanolamine-polyethylene glycol (2000)-folate].
- the central area of the core microparticle structure may comprise a gaseous label(s), examples include, but are not limited to, xenon-133, krypton-81m, nitrogen-13, technetium-99m DTPA).
- a gaseous label examples include, but are not limited to, xenon-133, krypton-81m, nitrogen-13, technetium-99m DTPA.
- microparticles not containing labels may also be suitable for ultrasound imaging.
- CT computed tomography
- X-ray X-ray
- further lipids for improving magnetic resonance imaging and nuclear magnetic resonance imaging may be included.
- the microparticle formulation may also comprise active, therapeutic or tag materials (examples include, but are not limited to, antibodies, peptides, drugs, radionuclide containing compounds, radiopharmaceuticals, radioactive gas, or genetic materials either (i) in the central area of the core microparticle structure, (ii) in/on the core microparticle shell, or (iii) both (i) and (ii). 53
- the microparticle composition comprises microparticles, wherein the microparticles comprise: a core microparticle structure having a central area and a shell, and at least one molecular binding element covalently attached to the shell of the core microparticle structure, wherein the core microparticle structure comprises: (i) a saturated Cio-20 phosphatidylcholine lipid; (ii) a saturated C 10-20 phosphatidylethanolamine lipid comprising a polyethylene glycol chain with a molecular weight of at least 1000, and at least one maleimide moiety; and (iii) a saturated C 10-20 polyethylene glycol fatty acid ester, wherein the microparticles possess a composition in which the molar ratio of (i) to (iii) satisfies the following ranges: (i) 70 to 80; (ii) 5 to 15; and (iii) 10 to 20, and the central area of the core microparticle structure comprises a physiologically acceptable gas selected from air,
- the core microparticle structure may comprise (i) DSPC as the saturated Cio- 2 0 phosphatidylcholine lipid; (ii) DSPE-PEG 2 ooo-Mal as the saturated Cio- 2 0 phosphatidylethanolamine lipid comprising a polyethylene glycol chain with a molecular weight of at least 1000, and at least one maleimide moiety; and (iii) PEG 4 o stearate as the saturated Cio- 2 0 polyethylene glycol fatty acid ester.
- the molar ratio of components (i) to (iii) may satisfy the following ranges: (i) 72 to 78; (ii) 7 to 12; and (iii) 12 to 18.
- the microparticle composition comprises microparticles, wherein the microparticles comprise: a core microparticle structure having a central area and a shell, and at least one molecular binding element covalently attached to the shell of the core microparticle structure, wherein the core microparticle structure comprises: (i) DSPC; (ii) DSPE-PEG 2 ooo-Mal; and (iii) PEG 4 o stearate, wherein the microparticles possess a composition in which the molar ratio of (i) to (iii) satisfies the following ranges: (i) 72 to 78; (ii) 7 to 12; and (iii) 12 to 18, the central area of the core microparticle structure comprises a physiologically acceptable gas selected from air, nitrogen, sulfur hexafluoride, chlorotrifluoromethane, dichlorodifluoro-methane, bromotrifluoromethane, bromochlorod
- This embodiment preferably also comprises a further phosphatidylethanolamine lipid in a molar ratio of 0.5 to 5, preferably 1 to 4, even more preferably 1.5 to 3.
- This further phosphatidylethanolamine lipid also prefereably comprises fatty acid chains of C 7 _ 24 , preferably Cg-22, more preferably Cio-2o > even more preferably saturated Cio-2o > most preferably it is a distearoylphosphatidylethanolamine (DSPE).
- DSPE distearoylphosphatidylethanolamine
- the microparticles containing the desired physiologically acceptable gas may be stored immediately after formation by freezing at, for example, -80 °C in an aqueous solution.
- the particles may be snap frozen in liquid nitrogen (with or without prior wash purification to remove, for example, unincorporated microparticle components or fragments). Then, to use the particles when needed, they may be warmed up by gently raising the temperature (e.g., by hand). This applies to microparticles with or without a molecular binding element(s) attached to the surface of the shell.
- the formed microparticles may also be stored as a lyophilisate (dry powder).
- the lyophilisate (powder) can be stored in an enclosed vial containing a desired physiologically acceptable gas in the headspace of the vial. Then, to use the particles when needed, they may be reconstituted by instilling a suitable aqueous-based solution (e.g., normal saline, 5% dextrose, 5% glucose, phosphate buffered saline (PBS) followed by shear- mixing (e.g., shaking by hand or a machine).
- a suitable aqueous-based solution e.g., normal saline, 5% dextrose, 5% glucose, phosphate buffered saline (PBS) followed by shear- mixing (e.g., shaking by hand or a machine).
- a suitable aqueous-based solution may comprise suitable additive(s), examples of the latter include but are not limited to, matrix agents (carbohydrates such as saccharide, maltose); cryoprotectants (such as propylene glycol, glycerol), buffers (sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate), pharmaceutically acceptable carrier/excipient, or a combination thereof.
- suitable additive(s include but are not limited to, matrix agents (carbohydrates such as saccharide, maltose); cryoprotectants (such as propylene glycol, glycerol), buffers (sodium phosphate monobasic monohydrate, sodium phosphate dibasic heptahydrate), pharmaceutically acceptable carrier/excipient, or a combination thereof.
- the present invention also concerns an intermediate microparticle composition suitable for producing a molecular imaging microparticle composition, wherein the intermediate composition comprises: (i) a phosphatidylcholine lipid; (ii) a phosphatidylethanolamine lipid comprising at least one maleimide moiety; and (iii) an alkoxylated fatty acid.
- a composition represents a stable intermediate formulation which may be used as the basis for forming or reforming microparticles, and can be easily stored, transported and then reformulated (with the required molecular binding element, where appropriate). Examples include (but are not limited to): (a) a lyophilisate (dry powder) of the microparticle components previously mixed and dissolved in a suitable organic solvent;
- the intermediate microparticle composition may have molar ratio of (i) to (iii) which satisfies the following ranges: (i) 70 to 80; (ii) 5 to 15; and (iii) 10 to 20.
- the intermediate microparticle composition may further comprise at least one molecular binding element.
- the at least one molecular binding element may be covalently attached to the at least one maleimide moiety.
- the intermediate microparticle composition is a lyophilisate.
- an intermediate composition may be prepared by providing a mixture comprising components (i)-(iii) in the molar ratio specified above. The components may be mixed by dissolving in a suitable solvent (e.g., chloroform) and then prepared for storage by lyophilisation.
- a suitable solvent e.g., chloroform
- the intermediate composition may share any of the features mentioned above in relation to the microparticle composition suitable for molecular imaging.
- the intermediate composition may comprise the same lipids and additional components.
- the intermediate composition may be prepared by providing a mixture comprising components (i) to (iii) in the molar ratio specified above.
- the components may be mixed by dissolving in a suitable solvent (e.g., cyclohexane hloroform in ratio 1:2) and then prepared for storage by lyophilisation.
- a suitable solvent e.g., cyclohexane hloroform in ratio 1:2
- Lyophilisation may allow exchange of the solvent to a suitable aqueous-based solution.
- Microparticles may then be formed by shear-mixing (e.g., using sonication, machine or hand agitation) of the intermediate composition in the presence of a desired physiologically acceptable gas.
- the microparticles formed may then be prepared for storage as a dry powder by lyophilisation, with/without prior wash purification to remove, for example, unincorporated microparticle components or fragments.
- the intermediate microparticle composition may be stored as a lyophilisate (dry powder).
- the lyophilisate dry powder
- the lyophilisate (powder) can be stored in an enclosed vial containing a desired physiologically acceptable gas in the headspace of the vial. Then, to use the particles when needed, they may be reconstituted by instilling a suitable aqueous-based solution followed by shear-mixing (e.g., shaking by hand or a machine).
- kits comprising an intermediate microparticle composition according to the invention, and a source of a fluid medium which comprises a physiologically acceptable gas.
- the physiologically acceptable gas may be selected from air, nitrogen, carbon dioxide, xenon, krypton, sulfur hexafluoride, chlorotrifluoromethane, dichlorodifluoro-methane, bromotrifluoro methane, bromochlorodifluoromethane, tetrafluoromethane, dibromo-difluoromethane, dichlorotetrafluoroethane, chloropentafluoroethane, hexafluoroethane, hexafluoropropylene, octafluoropropane, hexafluoro-butadiene, octafluoro-2-butene, octafluorocyclobutane, decafluorobutane,
- the kit may comprise an enclosed vial containing an aqueous (preferably micellar) lipid dispersion (e.g., a suspension of the lyophilisate in a suitable aqueous-based solution) with the physiologically acceptable gas in the headspace of the vial.
- an aqueous (preferably micellar) lipid dispersion e.g., a suspension of the lyophilisate in a suitable aqueous-based solution
- physiologically acceptable gas in the headspace of the vial.
- the kit may comprise an enclosed vial containing the intermediate microparticle composition as a lyophilisate (dry powder) with a physiologically acceptable gas in the headspace of the vial.
- the microparticles may be reconstituted by instilling a suitable aqueous-based solution followed by shear-mixing (e.g., shaking by hand or a machine).
- a method of preparing a microparticle composition comprising: forming a core microparticle structure having a central area and a shell from components (i) to (iii).
- the method may further comprise covalently attaching at least one molecular binding element to the shell of the core microparticle structure.
- the core microparticle structure having a central area and a shell may be formed in any suitable way. Commonly used methods for manufacturing microparticles involve, for example, high- shear mixing, such as sonication of an aqueous medium containing the shell-forming components.
- the solution (aqueous micellar dispersion, in case of lipids) may be sonicated with a probe-type ultrasound generator while gas is sparged through the solution. Gas is dispersed in the aqueous phase by ultrasound-induced shear. Microparticle gas particles are stabilized with the shell components immediately deposited at the gas-liquid interface.
- hand agitation or high-speed mixing can be used, as, for example, in dental amalgam processing.
- An enclosed vial with an aqueous micellar lipid dispersion and a gas headspace may be placed in an amalgamator. After a short (e.g. less than 1 minute) mixing (e.g. at approximately 2000-4000 rpm), microparticles are ready for use.
- microparticle shell components or microparticles may be prepared as dry precursors (lyophilisate).
- Microparticle shell components or microparticles may be codissolved or suspended, respectively, in a suitable solution with/without a suitable matrix agent (e.g. carbohydrate), placed in vials, and freeze-dried (lyophilised). Vials may then be filled with desired gas and sealed. Vials with the lyophilisate (dry powder) are very stable in storage. Immediately before use, they may be reconstituted with a suitable solution (e.g., 5% dextrose, or 5% glucose, or normal saline) and shear-mixed (e.g., shaking by hand or machine) to form the microparticles.
- a suitable solution e.g., 5% dextrose, or 5% glucose, or normal saline
- shear-mixed e.g., shaking by hand or machine
- a method of preparing a microparticle composition comprising: (i) shear-mixing (e.g., by sonication, or mechanical/hand agitation as described above) a suspension of components (i) to (iii) so as to form a core microparticle structure having a central area and a shell; and (ii) covalently attaching at least one molecular binding element to the shell of the core microparticle structure.
- the physiologically acceptable gas may be incorporated in step (i) of the above method, preferably by conducting the step in the presence of the gas.
- the microparticles may be prepared from the intermediate microparticle composition mentioned above.
- the lyophilisate (powder) may be resuspended with a suitable aqueous-based solution.
- the particles can then be formed using shear-mixing approaches in the presence of the desired gas (e.g., C 3 F 8 ), by sonication, hand agitation, or machine agitation (e.g., dental amalgamator at e.g., 2000-4000 rpm for e.g.
- the formed particles may then be washed prior to conjugation with molecular binding element. After conjugation, the particles may be washed (purified) to remove unconjugated molecular binding elements/bubble fragments etc. by spin-flotation with exchange of the subnatent with a physiologically suitable aqueous-based solution.
- Microparticles may also be regenerated from the lyophilisate (powder) of previously formed microparticles with or without molecular binding elements attached.
- the lyophilisate (powder) of the previously formed microparticles may be resuspended in a suitable aqueous- based solution.
- the particles may then be regenerated using shear-mixing approaches in the presence of the desired gas (e.g., C 3 F 8 ), by sonication, hand agitation, or machine agitation (e.g., dental amalgamator at e.g., 2000-4000 rpm for e.g.
- the desired gas e.g., C 3 F 8
- machine agitation e.g., dental amalgamator at e.g., 2000-4000 rpm for e.g.
- the regenerated microparticles are preferably purified to remove unincorporated microparticle components or fragments etc., prior to use or storage.
- the microparticles may be purified before conjugation with molecular binding elements.
- the microparticles are preferably purified to remove unconjugated molecular binding elements/bubble fragments etc., prior to storage.
- the microparticles are preferably purified first.
- microparticles re-formed from the lyophilisate may or may not be purified prior to use. Any suitable method can be used for the purification of microparticles. For example, washing by spin-flotation with exchange of the subnatent with a suitable solution or physiologically suitable aqueous-based solution.
- microparticles may be stored according to any of the following methods:
- Storage method 1 freezing of formed (washed or unwashed) microparticles (with or without molecular binding element(s) attached). This involves snap freezing and storing the microparticles at -80 °C with or without the desired gas in the headspace of the container.
- Storage method 2 lyophilisation of formed (washed or unwashed) microparticles (with or without molecular binding element(s) attached).
- a matrix agent e.g., carbohydrate
- a suitable aqueous-based solution may be added and then shear-mixed in the presence of desired gas (sonication or preferably hand/machine shaking).
- Storage method 3 lyophilisation of the lipid blend in organic solvent (thus making the initial lyophilisate) for microparticles with or without molecular binding element(s) attached.
- organic solvent e.g., cyclohexane hloroform
- a matrix agent e.g., carbohydrate
- the lyophilisate is dissolved in a suitable aqueous-based solution, then the solution may or may not be brought up to above the chain melting temperature (Tc) of the lipids in the mixture (e.g., 60-65 °C) prior to shear-mixing in the presence of the desired gas.
- Tc chain melting temperature
- the microparticles may be produced by carrying out the above steps (i) and (ii) in any order, i.e. the preparation method is not limited to carrying out step (ii) after step (i). Step (i) may be carried out first, followed by step (ii). Alternatively, step (ii) may be carried out first, followed by step (i).
- the molecular binding element(s) may be conjugated to the shell of the core microparticle structure via component (ii) prior to particle formation.
- the molecular binding element(s) may be mixed with component (ii) or the lipid-blend of components comprising component (ii). In either case, non-conjugated molecular binding elements may preferably be removed.
- the conjugated component (ii) containing the molecular binding element(s) may be purified prior to use.
- residual maleimide moieties (i.e. those containing active maleimide function) on component (ii) may be deactivated by, for example, hydrolysis or by reaction with excess thiols.
- Any suitable method for purification can be used, for example high-performance liquid chromatography (HPLC).
- Verification of the conjugated component can be by any suitable method, for example mass spectrometry, nuclear magnetic resonance, and amino acid analysis (depending on the nature of the molecular binding element(s) and/or reactants).
- the conjugation reaction used to covalently attach the molecular binding element to the shell of the core microparticle structure was found to be particularly effective when the conjugation reaction ratio used in the conjugation reaction is at least 2 x 10 6 molecular binding elements (e.g. antibody molecules) per microparticle.
- the conjugation reaction ratio may be at least 3 x 10 6 molecular binding elements per microparticle.
- the conjugation reaction ratio may be at least 4 x 10 6 molecular binding elements per microparticle.
- the conjugation reaction ratio used in the reaction to conjugate the molecular binding element to the microparticle is such that the conjugation reaction molar ratio of the at least one molecular binding element to component (ii) is >1:1. Otherwise, the conjugation reaction molar ratio of the at least one molecular binding element to component (ii) may be >5: 1. Further, the conjugation reaction molar ratio may be >8:1, >9:1, or >10: 1. In some embodiments, the conjugation reaction molar ratio may be about 10: 1.
- a pharmaceutical composition comprising a microparticle composition according to the invention, and a pharmaceutically acceptable carrier or excipient.
- a composition may comprise, for example, (i) microparticles having a single type of molecular binding element attached to the surface of the microparticles, (ii) microparticles having more than one type of molecular binding element attached to the surface of the microparticles, or (iii) a mixture of microparticles, each having a different molecular binding element attached to the surface of the microparticles.
- Pharmaceutically acceptable carriers that may be used in the pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminium stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulphate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene- polyoxypropylene-block polymers, polyethylene glycol and wool fat.
- ion exchangers alumina, aluminium stearate, lecithin
- serum proteins such as human serum albumin
- buffer substances such as phosphates, glycine, sorb
- the microparticle composition of the invention is suitable for use as a contrast agent in molecular imaging, for example ultrasound imaging, MRI, scintigraphy, SPECT, PET, CT, X-ray imaging/fluoroscopy, fluorescence imaging, bioluminescence imaging, microscopy, optical methods, or multi-modal variants thereof.
- molecular imaging for example ultrasound imaging, MRI, scintigraphy, SPECT, PET, CT, X-ray imaging/fluoroscopy, fluorescence imaging, bioluminescence imaging, microscopy, optical methods, or multi-modal variants thereof.
- the specific microparticle composition facilitates (i) minimal nonspecific retention in remote non-RES tissues not expressing the molecular moiety/moieties of interest (target molecule) following systemic or iv administration, (ii) effective real-time ultrasound molecular imaging, and (iii) acoustic quantification of the molecular moiety/moieties of interest to a high quantitative degree.
- the invention enables use of existing clinical ultrasound systems, whereby a low ultrasound-power non-linear (microparticle-specific) imaging mode (available on established clinical ultrasound systems) may be used.
- the low- power and real-time nature of the imaging technique is especially advantageous in terms of biosafety and the superior imaging information obtained. Continuous, multi-plane, or three- dimensional imaging with single microparticle-bolus administration is also feasible with this technology.
- microparticles in any form, or the intermediate composition, may be sterilised by a suitable method used in the art, such as by ultraviolet or gamma irradiation.
- an imaging method comprising: administering the microparticle composition of the invention, or a pharmaceutical composition thereof, to a subject; and imaging the subject using an imaging technique.
- the imaging technique may be one known extensively in the art, such as ultrasound imaging, MRI, scintigraphy, SPECT, PET, CT, X-ray imaging/fluoroscopy, fluorescence imaging, bioluminescence imaging, microscopy, optical methods, or multi-modal variants thereof.
- This method allows the imaging of the microparticles which are attached to a molecular moiety of interest as a result of the molecular binding element being bound to the molecular moiety.
- the molecular binding element of the microparticles is an Esel antibody
- the microparticles will bind to Esel (an endothelial adhesion molecule expressed on activated endothelium during inflammation) in the subject so that the imaging method allows the imaging detection for the presence/absence and location of Esel expression, as well as imaging quantification of the degree of Esel expression (and endothelial activation or inflammation) in the subject.
- the method also allows the imaging of microparticles which act as negative controls or calibration for molecular imaging.
- the imaging method allows the imaging of the presence/absence, location and degree of non-specific microparticle retention in the subject, or acts as negative control for imaging interpretation, or acts as a calibration agent for the imaging signals (e.g., signal intensity vs. known amount or concentration of microparticles administered).
- the subject may be any suitable subject.
- the subject is a mammalian subject such as a human.
- a microparticle composition suitable for molecular imaging comprising microparticles, wherein the microparticles comprise: a core microparticle structure having a central area and a shell, and wherein the core microparticle structure comprises (i) a phosphatidylcholine lipid, (ii) a phosphatidylethanolamine lipid; and (iii) an alkoxylated fatty acid.
- component (ii) of the microparticle composition may comprise at least one maleimide moiety
- the composition may further comprise a molecular binding element
- the components of the composition may be further defined as described above.
- the relative proportions of each component are equally applicable in relation to this aspect of the invention.
- FIG. Frozen section immunohistochemistry of the mouse heart. Representative example from mice 6h post lipopolysaccharide (LPS) pre-treatment. Magnification 200x. Low power magnification (low mag) 40x.
- LPS lipopolysaccharide
- FIG. 1 Real-time ultrasound (US) molecular imaging of Esel expression in the mouse heart, (a) Sequential 14MHz Contrast Pulse Sequencing (CPS) images of the heart in end-diastole parasternal short- axis (PSA) view, in a (1) WT and (2) Esel KO mouse pre-treated with LPS, respectively.
- US real-time ultrasound
- CPS Sequential 14MHz Contrast Pulse Sequencing
- PSA end-diastole parasternal short- axis
- TICs of the LV cavity (from region of interest (ROI) C) and myocardium (from ROI M) for the respective animal are shown beneath; each data point represents background subtracted mean signal intensity (I) +SD; suggested bolus (B), distribution (D) and elimination- phase (E) of the time signal intensity curve (TIC) are indicated, (b) PSA, parasternal long-axis (PLA) and apical 4-chamber (A4C) views of the heart at 14 and 7MHz CPS, >20min post particle administration (when freely circulating-particles have cleared from the blood pool (left ventricular (LV) cavity)). Animal, gain and MI were the same between both frequencies. Arrow indicates mid anteroseptal wall. Baseline images before particle administration are shown in Figure 6.
- FIG 5a Real-time US molecular imaging of Esel expression in the mouse abdomen. Combined 14MHz 'CPS-contrast only' and 'B-mode images' before (i, ii, v, vi) and ⁇ 30min post (iii, iv, vii, viii) particle administration. Kidney (K), liver (L), spleen (S).
- Figure 5b Real-time US molecular imaging of Esel expression in the mouse lower abdomen. Separate 14MHz 'CPS-contrast only' and 'B-mode images' before (ix, x, xiii, xiv) and ⁇ 30min post (xi, xii, xv, vxi) particle administration. Kidney (K), spleen (S).
- FIG. 7 Temporal expression of Esel in the mouse heart, (a) Esel mRNA. Each data point represents one animal. Exponential line of best fit +95% confidence interval (CI) is shown, (b) Esel cell-surface protein. Each data point represents mean +95% CI for 5, 5, 4, 5 mice at LPSxi me 3, 5, 8, 24h, respectively. Exponential line of best fit +95% CI is shown, (c) Esel mRNA vs. Esel cell-surface protein.
- CI Exponential line of best fit +95% confidence interval
- MES-1 monoclonal antibody a rat IgG2a,£ against mouse Esel, 10 and its F(ab') 2 fragment (MES-1 F(ab') 2 ) were provided by Dr D Brown (UCB Celltech, UK).
- AF488-MES-1 MES-1 labelled with 7 Alexa Fluor® 488 fluorescence dye
- MES-1 F(ab') 2 Reduction of MES-1 F(ab') 2 for microparticle conjugation.
- MES-1 F(ab') 2 was reduced using 4 molar excess TCEP (Sigma-Aldrich): MES-1 F(ab') 2 (83.3 ⁇ , 8.3mg/ml) and
- TCEP (333.3 ⁇ , 0.096 mg/ml) in Exchange Buffer (50mM 2-(N- Morpholino)ethanesulfonic acid (Sigma-Aldrich), 2mM ethylenediaminetetraacetic acid (Sigma-Aldrich), pH 6) were incubated for lh at 37°C under constant agitation. The reaction volume ranged 1-1.6ml. The reaction was stopped by placing on ice and immediate purification of the reduced F(ab') 2 using spin column gel filtration chromatography with a 5ml-Zeba Desalt Spin Column (size exclusion limit l,000Da) according to the manufacturer's instructions (Perbio Science), at 4°C.
- Exchange Buffer 50mM 2-(N- Morpholino)ethanesulfonic acid (Sigma-Aldrich), 2mM ethylenediaminetetraacetic acid (Sigma-Aldrich), pH 6) were incubated for lh at 37°C
- the spin column was previously equilibrated in cold Exchange Buffer.
- the degree of reduction of the F(ab') 2 was determined spectrophotometrically using Ellman's test with Ellman's Reagent (Perbio Science) according to the manufacturer's instructions with the following modifications: the Ellman's reaction consisted of 2.5 ⁇ Ellman's Reagent (lOmM, 4mg/ml), 7.5 ⁇ 1 Exchange Buffer and 90 ⁇ 1 of the purified reduced F(ab') 2 in Exchange Buffer, incubated at room temperature (rt) covered with aluminium foil to minimise light exposure; absorbance at 412nm (A 4 i 2 ) was measured at 24min from the start of the Ellman's reaction, to determine the concentration of SH in the reduced F(ab') 2 sample by reference to a standard curve of Ellman's reaction with known concentrations of SH-containing compound, L-Cysteine hydrochloride (Perbio Science) in Exchange Buffer (
- the purified reduced F(ab') 2 was kept at concentration of ⁇ 8mg/ml (80 ⁇ ) in Exchange Buffer for subsequent conjugation to microparticles.
- a ⁇ -labelling reaction mixture consisting of 50 ⁇ MES-1 mAb (25.7 ⁇ 1 at 194 ⁇ or 29.1mg/ml in phosphate buffered saline (PBS) pH 7.5), 750 ⁇ AF488 (6.6 ⁇ 1 at 11.3mM or lOmg/ml in water), 2.6 ⁇ 1 (1/10 ⁇ volume of MES-1 mAb added) 1M NaHC03 pH 8.5 and 65.1 ⁇ 1 distilled H 2 0, was incubated at rt for lh, with gentle manual agitation at 30min. Controls included no dye or no MES-1 mAb.
- AF488 -labelled MES-1 was then purified from the reaction mixture and suspended in PBS (pH 7.5), using gel-filtration chromatography spin column with 6kDa size exclusion limit (Bio-Spin P-6 Column with SSC packing buffer, BioRad) according to the manufacturer's instructions with the following specific conditions: the Bio-Spin column was buffer exchanged first with PBS using 3 wash cycles; all centrifugations were carried out at 20°C.
- AF488-labelled MES-1 was determined using a spectrophotometer. Samples were diluted in PBS to ⁇ volume in duplicates, and absorbance measured at 280nm (A 28 o) and 495nm (A 4 9s). The concentration of the labelled mAb was calculated as:
- C 3 F 8 Native (unconjugated) maleimide-functionalised lipid-shelled octafluoropropane (C 3 F 8 ) microparticles were prepared by sonication of an aqueous suspension containing 1,2-distearoyl- sft-glycero-3-phosphocholine (DSPC; Avanti Polar Lipids, AL), l,2-distearoyl-5n-glycero-3- phosphoethanolamine-N-(maleimide(polyethylene glycol)-2000) (DSPE-PEG 2 ooo-Mal; Avanti Polar Lipids), mono-stearate poly(ethylene)glycol (PEG 4 o stearate; Sigma-Aldrich), and fluorescent dye l, -dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (Dil; Molecular Probes) at 75:9: 14:2 molar ratio,
- TCEP-reduced MES-1 F(ab') 2 containing 2 SH groups per F(ab') 2 were grafted to the shell outer-surface of these native particles by maleimide-thiol conjugation.
- the conjugation reaction ratio was 4.338xl0 6 F(ab') 2 molecules per particle (7.2nmol F(ab') 2 per 10 9 particles).
- Particles were washed with cold degassed normal saline using multiple cycles of centrifugation flotation under C 3 F 8 atmosphere at 4°C before and after particle conjugation, to remove unincorporated components and particle fragments. Freshly prepared particles were immediately divided into 20-50 ⁇ 1 aliquots, capped and sealed with parafilm (American National Can), then snap frozen in liquid nitrogen and stored at -80°C until use. The concentration of subsequently thawed Esel targeting particles ranged 1- 3xl0 9 particles/ml amongst 5 batches prepared at different times.
- the dry powder (lyophilisate) was then dispersed in a suitable aqueous-based solution (e.g., normal saline or normal saline containing 0.01% propylene glycol (PGNS: propylene glycol 103.5mg/ml, glycerol 126.2mg/ml, NaCl 6.8mg/ml, pH -7.4)), to a concentration of 4mg/ml, homogenised by sonication in an ultrasonic bath at 60-65 °C until transparent. Once fully dissolved, the solution was gently sparged with C 3 F 8 gas (F2 Chemicals).
- a suitable aqueous-based solution e.g., normal saline or normal saline containing 0.01% propylene glycol (PGNS: propylene glycol 103.5mg/ml, glycerol 126.2mg/ml, NaCl 6.8mg/ml, pH -7.4
- PGNS propylene glycol 10
- Microparticles were then formed using a shear- mixing approach, by sonic dispersion of C 3 F 8 using a sonicator (Misonix 3000, QSonica, CT).
- the probe tip was positioned about 2mm into the solution and sonication was performed with a high-intensity ultrasound horn (20-21 kHz) for 30-60s at an acoustic power of approximately 120W with an initial temperature of approximately 60°C.
- More C 3 F 8 gas was sparged into the microbubble dispersion, and the vessel capped and immediately plunged into ice cold water (3min) to dissipate the heat generated during the sonication process.
- Microparticles produced were washed (purified) by centrifugation flotation at l,000g 4°C for 15-25min, using a Beckman Coulter Allegra X-15R Centrifuge (Beckman Coulter): particles float to the top of the sample vial after centrifugation, the subnatent was removed and replaced with equal volume of cold degassed normal saline (pH 7.4). The wash step was repeated 7 times to remove unincorporated shell components and particle fragments. To produce Esel targeting microparticles, these washed native microparticles were added to reduced MES-1 F(ab') 2 whilst mixing (each reduced F(ab') 2 molecule contained 2 SH groups, prepared as described above).
- the conjugation reaction ratio used to produce the successful Esel targeting particles was 4.338xl0 6 F(ab') 2 molecules per particle.
- the concentration of particles and F(ab') 2 in the conjugation reaction mixture ranged 5- 8xl0 9 /ml and 35-60uM (3.5-6mg/ml), respectively.
- the reaction mixture contained approximately 2/3 volume of Exchange Buffer (pH 6) from the reduced F(ab') 2 and 1/3 volume of normal saline (pH 7.4) from the washed particles.
- the conjugation reaction was incubated at 4°C for 30min, continuously mixed gently on a vertically tilted rotating wheel.
- Particle conjugation was terminated by adding 80mM NEM (Sigma-Aldrich) dissolved in dry dimethyl sulfoxide (DMSO, Sigma-Aldrich) at 20 molar excess to F(ab') 2 - the reaction mixture was incubated at 4°C for 30-60min on the rotator. Typically, the concentration of NEM and DMSO in the reaction mixture was -lmM and ⁇ 1.7% v/v, respectively. The particles were then washed 4 times with cold normal saline by centrifugation flotation as described above, at 160g 4°C for 5min. This removed unincorporated F(ab') 2 , unreacted NEM, DMSO and particle-fragments.
- NEM Sigma-Aldrich
- DMSO dry dimethyl sulfoxide
- Particle integrity was examined under microscopy with the particles placed in a haemocytometer (Reichert Bright-Line Metallized Hemocytometer, Hausserscientific, PA) at e.g., 1:200 dilution in cold normal saline.
- Particle concentration and size distribution were determined by electrozone sensing in a Coulter Multisizer He equipped with a 30 ⁇ m-diameter orifice counting tube (Coulter Electronics), according to the manufacturer's instructions. The set-up allowed size detection range 0.72-18 ⁇ , resolution 0.09 ⁇ .
- the particles were dispersed in 1ml of ImM KC1 (pH 7.4) at -10 particles/ml. Its net charge was determined as the zeta potential by light scattering in a Zetasizer Nano ZS (Malvern Instruments), according to the manufacturer's instructions.
- ⁇ of Esel targeting or non-targeting (native) particles at 2.5x10 particles/ml were placed on inverted polystyrene petri-dishes coated with 200 ⁇ 1 of recombinant homodimeric mouse Esel protein (R&D Systems) at 7nM (dish E), or on Esel coated dishes previously blocked with 500 ⁇ 1 of excess MES-1 F(ab') 2 at 67nM (dish B), or on non-coated dishes where phosphate buffered saline pH 7.5 (PBS) was used instead of Esel for dish coating (dish P). Unattached particles were gently washed off after lmin. The dishes were then re-filled with cold degassed PBS for immediate examination under an upright light microscope equipped with immersion objective lens. The number of particles attached on each dish was counted and averaged from 10 random optical fields (OFs) to determine the attached particle density.
- R&D Systems homodimeric mouse Esel protein
- PBS phosphate buffere
- Unattached particles were then gently washed off and the dishes re-filled with cold degassed PBS for immediate examination using an upright light microscope equipped with immersion objective lens, connected to a camera and monitor.
- the number of particles attached to each dish was counted and averaged from 10 random optical fields (OFs) on the monitor display, the surface area of the latter determined using a stage micrometer. The attached particle density was thus determined.
- OFs random optical fields
- Wild-type mice adult male C57B16/Jax (Charles River, UK).
- Esel knock-out mice adult male Esel homozygote KO on C57B16 background, 57 bred locally from mice donated by Dr K Norman and Prof P Hellewell (University of Sheffield, UK). All the animal work was carried out under Project Licences and Personal Licences granted by the Home Office under the Animals (Scientific Procedures) Act 1986; ethical approval was additionally obtained from the local Ethical Review Panel.
- LPS Lipopolysaccharide
- WT and Esel KO mice were pre-treated with 50 ⁇ g LPS from E Coli 0111:B4 (Sigma- Aldrich), made up to 200 ⁇ 1 volume in normal saline, by intraperitoneal ⁇ ip) injection to induce systemic inflammation.
- LPS from E Coli 0111:B4 (Sigma- Aldrich)
- ip injection produces systemic inflammation, which includes induction of Esel expression in multiple organs including the heart and kidneys.
- This animal model differs from others used in particle-targeting (such as ischaemia- reperfusion injury, heart transplant rejection, thrombosis, chronic-ischaemia/tumour angiogenesis animal models) in that: (i) it does not require surgical procedures which may introduce confounding variables such as surgical trauma or blood clots; (ii) the particles target molecules present in multiple organs (not just one), uniquely allowing assessment of targeting particle specificity in multiple organs simultaneously, and assessing the imaging technique's ability to detect target molecule in a tissue of interest in the presence of 'particle steal' by other tissues; and (iii) the target molecule expression in the myocardium was essentially global and uniform, uniquely allowing the study of targeted particle signal attenuation.
- particle-targeting such as ischaemia- reperfusion injury, heart transplant rejection, thrombosis, chronic-ischaemia/tumour angiogenesis animal models
- Esel being solely expressed on activated endothelial cells and its essentially global uniform expression in the myocardium of LPS pre-treated mice, makes the LPS mouse model-Esel combination an ideal in vivo model for testing acoustic quantification of molecular expression.
- RNAlater® solution (Ambion) to preserve ribonucleic acid (RNA) in-situ; total RNA was subsequently extracted using TRIzol reagent (Invitrogen) according to the manufacturer' s instructions.
- cDNA First-strand complementary deoxyribonucleic acid
- the primer sequences were: Esel forward primer 5 ' -CTC ATTGCTCTACTTGTTGATG-3 ' , Esel reverse primer 5'- GC ATTTGTGTTCCTGATTG-3 ' , HPRT-I forward primer 5 ' - ATTAGCGATGATGAACCAG- 3' , HPRT-I reverse primer 5 ' - AGTCTTTC AGTCCTGTCC AT-3 ' .
- the threshold cycle (Ct) was determined from the amplification plot using the iCyclerTM iQ Optical System Software Version 3.0a (Bio-Rad).
- RNA from the mouse heart was typically ⁇ g pure RNA per lmg tissue, kept at concentrations over ⁇ lmg/ml in molecular grade (RNase-free) H 2 0 (Sigma- Aldrich).
- the RT reaction mixture for first-strand cDNA synthesis consisted of ⁇ g total RNA, 2 ⁇ 1 ⁇ buffer RT, 2 ⁇ 1 deoxyribonucleotide triphosphate (dNTP) mix (5mM each 2'-deoxyadenosine 5'-triphosphate (dATP), 2'-deoxycytidine 5'- triphosphate (dCTP), 2'-deoxyguanosine 5'-triphosphate (dGTP), 2'-deoxythymidine 5'- triphosphate (dTTP), 1 ⁇ (4 units) Omniscript reverse transcriptase, 2 ⁇ 1 ( ⁇ g) oligo(dT)i 2 -i8 primer (Invitrogen) and molecular grade H 2 0 made up to a total
- qPCR was carried out in a volume in each well of a 96- well 0.2ml thin-wall PCR plate (Bio-Rad) covered with an Optical Quality Sealing Tape (Bio- Rad).
- the qPCR reaction mixture consisted of 5 ⁇ 1 cDNA template (1 :50 water dilution of the finished RT reaction), 0.5 ⁇ 1 (10 ⁇ ) each of the forward and reverse primer for the respective gene (see text for primer sequence; the primers were custom ordered from Invitrogen), 6.5 ⁇ 1 molecular grade H 2 0 and 12.5 ⁇ 1 iQTM SYBR® Green Supermix (Bio-Rad).
- the qPCR cycling condition was: initial 3min denaturing step at 95°C (Well Factor analysis in first 90s); then 40 cycles of 15s at 95°C, lmin at 56°C; melt-curve analysis in 0.5°C steps (lmin denaturation at 95°C, lmin reset at 56°C, then 80 cycles of 10s at 60°C with 0.5°C increment for each cycle); final cooling step at 4°C.
- Esel and HPRT-I were amplified on the same plate for each animal; no- template negative control using molecular grade H 2 0 in place of cDNA template for both primer pairs were included in all plates. For data analysis, wells with abnormal amplification plot or melt-curve were excluded.
- IVMS Intravital Microscopy
- Inflammation of the cremaster muscle was produced by intrascrotal injection of 50ng recombinant IL- ⁇ (R&D Systems) 2h before surgery in WT and Esel KO mice.
- the tail vein was cannulated with a 24G 0.7x19mm intravenous (z ' v) catheter (dead space ⁇ 50 ⁇ 1) (BD Medical).
- Long duration anaesthesia was achieved using intraperitoneal (ip) injection of 200- 300 ⁇ 1 mixture containing lmg/ml xylazine (Rompum, Bayer) and lOmg/ml ketamine hydrochloride (Ketalar, Parke-Davis) in normal saline.
- the animal was placed on a custom-built thermo-controlled (37°C) IVM stage. Under a dissection microscope, the right or left testis was gently exteriorised through a scrotal incision. A longitudinal incision was made along the cremaster muscle, which was then spread out and pinned down across a translucent microscopy stage. The exteriorised muscle was maintained by continuous super-fusion of thermo-controlled Tyrode's Salt buffer solution (9.6g Tyrode's Salts (Sigma-Aldrich) + lg sodium hydrogen carbonate, made up to 1L volume with sterile distilled water).
- Tyrode's Salt buffer solution (9.6g Tyrode's Salts (Sigma-Aldrich) + lg sodium hydrogen carbonate, made up to 1L volume with sterile distilled water).
- V r bc microvascular centreline red blood cell velocities
- V r i, c were measured in 20-40 ⁇ diameter venules from 5 random vessel- segments per animal, using an Optical Doppler Velocimeter before particle injection. All recordings were made using a S-VHS recorder and Personal Computer. All animals were sacrificed at the end of the experiment. See above for details of the set-up. Blood flow and particles were assessed over several OFs encompassing a number of different vessels under bright field and fluorescence microscopy. The number of freely circulating-particles in an OF on the monitor were counted over 10s under fluorescence microscopy at 5, 7, 10 + 15min after particle injection.
- the accumulation of attached particles (defined as not moving for >3s) in an OF field were assessed for up to 15min post particle injection.
- the number of particles attached to 20-40 ⁇ diameter venules were counted at ⁇ 15min after particle injection (when freely circulating -particles were absent/minimal) from 1-5 400 ⁇ length segments per venule, 2- 6 venules per animal.
- the attached particles in the same OF were followed-up for up to 90min using intermittent combined bright field and fluorescence microscopy, looking for the presence/absence of transmigration into the tissue interstitium or cellular internalisation.
- VSA number of particles per vessel surface area
- VSA (mm 2 ) D(mm) x L ⁇ mm)
- D and L were the vessel segment diameter and length, respectively.
- the attached particle density for each venule was taken as the mean of its segments, and that for each animal was taken as the mean of its venules.
- the cremaster muscle was then harvested immediately, spread out and fixed in 4% paraformaldehyde PBS solution for 30min at rt, then placed in cold PBS at 4°C for 5min. Aluminium foil was used to minimise light exposure to the tissue.
- Fresh tissues were examined immediately under confocal microscopy (z-stacked), using an upright confocal laser- scanning microscope (LSM 5 PASCAL, Carl Zeiss) with a 40x immersion objective lens (Water Achroplan, Carl Zeiss).
- WT and Esel KO mice were all pre-treated with LPS, tail vein cannulated and anaesthetised with xylazine/ketamine mixture as described above. The chest, abdomen and pelvis were then shaved and the animal placed supine. ECG electrode pads (Ambu® Blue Sensor P, Ambu) were applied to the paws and connected to the US machine (Acuson Sequoia® 512 US system, Siemens, CA) equipped with 'Small Animal ECG Filter' . A layer of warm gel (Gel for ultrasonic & electrical transmission, Henleys Medical) was coupled between the skin and US transducer (15L8-S linear array transducer, foot print 26mm, Siemens).
- baseline parasternal short axis (PSA) view at the papillary muscle level, parasternal long axis (PLA) and apical 4-chamber (A4C) views of the heart with and without 'regional expansion selection' (RES; giving magnified images with enhanced resolution) were recorded as 3s-digital clips. Thereafter, imaging was maintained in the PSA view with the transducer fixed in position using a free standing clamp. A stopwatch was then started and 1x10 Esel targeting particles (in ⁇ volume made up with normal saline) injected at 10s via the tail vein catheter as a rapid iv bolus over l-2s, followed by a ⁇ -normal saline flush over l-2s at 20s.
- Videodensitometric method was used to quantify particle signal intensity off-line, using the YABCO software (LLC Charlottesville, Virginia). End-diastolic image frames of the heart in the PSA view ('CPS -contrast only' images) were selected and aligned, those that could not be aligned (e.g., due to large movement artefact) were excluded. Regions of interest (ROIs) were placed on the mid-anterior wall of the myocardium (M) and adjacent region in the LV cavity (C), as shown in Figure 4a. These regions were chosen because they were consistently least or minimally affected by US attenuation in all animals. The video signal intensities (VI) were
- Linearised VI 255x 10 255 20 , where dB is the dynamic range (55dB in this study).
- Linearised VI (/) was expressed in arbitrary acoustic units (AU). / of several end-diastolic image frames within the 3s-recording period at each time point were averaged, then corrected for background noise by subtracting away average / of the baseline images (images before particle administration) in the respective animals.
- TICs of the myocardium (tissue) and LV cavity (central blood pool) were constructed by plotting background- subtracted / of the myocardium and LV cavity, respectively, against time post particle administration.
- the TIC-based method also allowed other variables to be determined simultaneously, including the retained- and circulating-microparticle half-life in vivo.
- the LPS Time for US molecular imaging was taken as the duration between the time of LPS pre- treatment and administration of the targeting microparticles.
- the particles were sufficiently echogenic, stable, lacked non-specific binding, and produced no immediate adverse effects in vivo. Particles made using other compositions did not exhibit all of these desired properties.
- the suitable native particles also contained enough maleimide groups for conjugating sufficient targeting elements onto the particle surface for efficient target binding under flow conditions.
- the conjugation reaction ratio used to produce the successful Esel targeting particles was 4.338xl0 6 F(ab')2 molecules per particle.
- Lower F(ab')2:particle reaction ratio lxl0 6 :l produced particles that could only attach to target under static conditions.
- the site-directed maleimide-thiol conjugation of targeting ligands to particles described herein is a departure from the immunogenic (strept)avidin-biotin conjugation chemistry traditionally used in preparing targeting particles.
- the site- directed maleimide-thiol conjugation method was advantageous due to its low immunogenicity, strong and rapid thioether bond formation at near neutral pH (bond strength in the order of nanonewtons; second-order rate constant 0.8-lxlO 4 M ' V 1 ).
- the near neutral pH was advantageous in avoiding negative impact on the binding elements and particles during preparation, and prevents dissociation of the binding elements from the particle shell in vivo.
- Targeting particles based on similar conjugation chemistry including non-covalent conjugation of targeting ligands to a phospholipid species before particle assembly, exist but only a few are progressing to ultrasound molecular imaging in vivo, 44'47 ' 61-64 none of which showed all of the following desirable attributes which differentiate our microparticles from them: (i) high target binding specificity with proven minimal non-specific retention in remote non-RES tissues not expressing the target molecule, following iv administration; (ii) effective for real-time US molecular imaging; and (iii) effective for acoustic quantification of molecular targets to a high quantitative degree.
- Esel targeting particles were administered to 5 WT (body weight: 25(mean) +2(SD) g, range 23- 27g)) and 5 Esel KO (24 +2g, range 22-27g) mice at 3:06-4:03h and 3: 17-4:30h post IL- ⁇ pre- treatment, respectively.
- the particles were seen to circulate and reach the cremaster muscle ⁇ 7- 17s post iv bolus administration through the tail vein.
- the number of freely circulating-particles decreased with time, their clearance from the blood pool occurred sooner in the WT than KOs, Figure 3a. Beyond lOmin after particle administration, the number of freely circulating-particles in the blood pool was minimal or undetectable in all animals.
- Non-linear CPS artefacts present both before and after particle administration could be seen in WT and Esel KO animals; these artefacts were small and outside the myocardium, Figure 4a (frame 0: 10), Figure 4a2 (frame 20:20).
- particle signal was first detected in the right heart chambers within 4 heart beats ( ⁇ ls), the signal intensity rose rapidly. This was followed by the appearance of particle signal in the left heart chambers as the particles returned from the pulmonary circulation. Particle signal intensity in the LV cavity and myocardium peaked within 6-7 heart beats ( ⁇ 1.5-2s) and 9-12 heart beats ( ⁇ 2-3s) after particle administration, respectively.
- High particle concentration resulted in signal saturation/attenuation, obscuring re-circulation peaks.
- the particle signal intensity was frequently observed to paradoxically increase as attenuation decreased, giving rise to a second lower peak within 0.5-lmin of particle administration (arrow in insets of Figure 4a).
- Particle signal intensity in the LV cavity (representing freely circulating-particle concentration in the central blood pool) became undetectable sooner in the WT than Esel KO animals; in both groups they were essentially undetectable by 20min post particle administration.
- particle signal intensity of WT animals decreased slower than that of KOs, and persisted beyond the disappearance of particle signal in the LV cavity.
- particle signal in the myocardium became undetectable before the disappearance of particle signal in the LV cavity (as expected for relative myocardial blood volume (rMBV) ⁇ 24%), except when a detectable degree of non-specific particle retention was present.
- mice were used. 12 WT (age 5.7(mean) +0.3(SD) weeks, range 5.1-6.1 weeks; body weight 19.7(mean) +1.4(SD) g, range 18-22g) and 8 Esel KO (age 7.9 +3.2 weeks, range 5-13.6 weeks; body weight 22.3 ⁇ 3.7g, range 17-28g) mice were used. LPSxi me ranged 3:53-5:59h for the WT and 4:27-5:39h for the KO group. Excluded from quantitative analysis here were used.
- 0.1 AU in the LV cavity would contribute only 0.005-0.024 AU in the myocardium assuming a relative myocardial blood volume (% of myocardium that is blood) of ⁇ 5-24%.
- the elimination of the retained-particles in the myocardium decreased with increased maximum concentration of retained-particles in the myocardium. The relationship was non-linear and could be empirically fitted to an exponential or sigmoidal function. This resulted in the half-life of the retained-particles being shorter the lower the maximum retained-particle concentration.
- the microparticles are specific and effective in vivo for highly quantitative real-time ultrasound molecular imaging of one or more organs.
- the microparticles have favourable characteristics in vivo which include, but are not limited to, being non-toxic, sufficiently stable for continuous and multi-plane imaging with a single-bolus microparticle administration, having favourable kinetics and acoustic response for highly quantitative analysis of the molecular moiety of interest. They have sufficiently high targeting specificity and efficiency to the molecular moiety of interest in vivo, and lack non-specific binding/persistence in tissues not expressing the molecular moiety of interest (except in the liver and spleen which are the usual routes of microparticle elimination in the body). In conclusion, these targeting microparticles are different and superior to the prior art. References
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201380072860.XA CN105188769B (en) | 2012-12-21 | 2013-12-20 | Microparticle compositions |
US14/654,650 US20160058893A1 (en) | 2012-12-21 | 2013-12-20 | Microparticle compositions |
JP2015548772A JP6495828B2 (en) | 2012-12-21 | 2013-12-20 | Fine particle composition |
EP13821508.2A EP2934599B1 (en) | 2012-12-21 | 2013-12-20 | Microparticle compositions |
US17/823,236 US20230066723A1 (en) | 2012-12-21 | 2022-08-30 | Microparticle compositions |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1223332.6A GB201223332D0 (en) | 2012-12-21 | 2012-12-21 | Microparticle compositions |
GB1223332.6 | 2012-12-21 | ||
GB1300064.1A GB2511032A (en) | 2012-12-21 | 2013-01-03 | Microparticle compositions |
GB1300064.1 | 2013-01-03 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/654,650 A-371-Of-International US20160058893A1 (en) | 2012-12-21 | 2013-12-20 | Microparticle compositions |
US17/823,236 Division US20230066723A1 (en) | 2012-12-21 | 2022-08-30 | Microparticle compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014096859A1 true WO2014096859A1 (en) | 2014-06-26 |
Family
ID=49958498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2013/053398 WO2014096859A1 (en) | 2012-12-21 | 2013-12-20 | Microparticle compositions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014096859A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008131217A1 (en) * | 2007-04-20 | 2008-10-30 | Oregon Healty & Science University | Ultrasound imaging with targeted microbubbles |
WO2011038043A1 (en) * | 2009-09-22 | 2011-03-31 | Targeson, Inc. | Optical imaging contrast agents and uses therof |
-
2013
- 2013-12-20 WO PCT/GB2013/053398 patent/WO2014096859A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008131217A1 (en) * | 2007-04-20 | 2008-10-30 | Oregon Healty & Science University | Ultrasound imaging with targeted microbubbles |
WO2011038043A1 (en) * | 2009-09-22 | 2011-03-31 | Targeson, Inc. | Optical imaging contrast agents and uses therof |
Non-Patent Citations (6)
Title |
---|
B. A. KAUFMANN ET AL: "Molecular Imaging of Inflammation in Atherosclerosis With Targeted Ultrasound Detection of Vascular Cell Adhesion Molecule-1", CIRCULATION, vol. 116, no. 3, 17 July 2007 (2007-07-17), pages 276 - 284, XP055020746, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.106.684738 * |
KLIBANOV A L: "LIGAND-CARRYING GAS-FILLED MICROBUBBLES: ULTRASOUND CONTRAST AGENTS FOR TARGETED MOLECULAR IMAGING", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 16, no. 1, 1 January 2005 (2005-01-01), pages 9 - 17, XP001222916, ISSN: 1043-1802, DOI: 10.1021/BC049898Y * |
LANZA G M ET AL: "TARGETED ULTRASONIC CONTRAST AGENTS FOR MOLECULAR IMAGING AND THERAPY", PROGRESS IN CARDIOVASCULAR DISEASES, SAUNDERS, PHILADELPHIA, PA, US, vol. 44, no. 1, 1 July 2001 (2001-07-01), pages 13 - 31, XP008034236, ISSN: 0033-0620, DOI: 10.1053/PCAD.2001.26440 * |
VILLANUEVA ET AL: "Molecular imaging of cardiovascular disease using ultrasound", JOURNAL OF NUCLEAR CARDIOLOGY, MOSBY, ST. LOUIS, MO, US, vol. 15, no. 4, 1 July 2008 (2008-07-01), pages 576 - 586, XP023313591, ISSN: 1071-3581, [retrieved on 20080729], DOI: 10.1016/J.NUCLCARD.2008.05.005 * |
YEH J S M ET AL: "Molecular imaging of the heart using contrast ultrasound: acoustic quantification of molecular expressions", EUROPEAN HEART JOURNAL, vol. 29, no. Suppl. 1, September 2008 (2008-09-01), & ANNUAL CONGRESS OF THE EUROPEAN-SOCIETY-OF-CARDIOLOGY; MUNICH, GERMANY; AUGUST 30 -SEPTEMBER 03, 2008, pages 21, XP002723002 * |
YOICHI NEGISHI ET AL: "AG73-modified Bubble liposomes for targeted ultrasound imaging of tumor neovasculature", BIOMATERIALS, vol. 34, no. 2, 22 November 2012 (2012-11-22), pages 501 - 507, XP055112949, ISSN: 0142-9612, DOI: 10.1016/j.biomaterials.2012.09.056 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230066723A1 (en) | Microparticle compositions | |
JP4215820B2 (en) | Novel targeted compositions for diagnostic and therapeutic uses | |
US20050175541A1 (en) | Enhanced drug delivery | |
Liu et al. | Ultrasound molecular imaging of acute cardiac transplantation rejection using nanobubbles targeted to T lymphocytes | |
JP2007511616A5 (en) | ||
AU2002213285B2 (en) | Novel targeted compositions for diagnostic and therapeutic use | |
JP2009535126A (en) | Target tissue detection and imaging | |
US10912848B2 (en) | Dual-purpose PAT/ultrasound contrast agent bound with nanoparticles containing drug and method for preparing same | |
CZ149499A3 (en) | Diagnostic and/or therapeutic preparation | |
Yan et al. | A lipopeptide-based αvβ3 integrin-targeted ultrasound contrast agent for molecular imaging of tumor angiogenesis | |
JP2001511765A (en) | Improved diagnostic / therapeutic agents | |
US20210321985A1 (en) | Compositions and methods for targeted contrast agents for molecular imaging | |
US20200000944A1 (en) | Molecular imaging contrast agents and uses thereof | |
Spivak et al. | Low-dose molecular ultrasound imaging with E-selectin-targeted PBCA microbubbles | |
US6811766B1 (en) | Ultrasound imaging with contrast agent targeted to microvasculature and a vasodilator drug | |
WO2014096859A1 (en) | Microparticle compositions | |
KR20140065763A (en) | Ultrasound contrast agent capable of liver cancer specific targetting and method for preparing the same | |
CZ149599A3 (en) | Diagnostic and/or therapeutical preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201380072860.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13821508 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015548772 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14654650 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013821508 Country of ref document: EP |